Joseph Murphy is an experienced professional in the field of clinical operations and research, currently serving as the Director Clinical Operations Lead II at Astellas Pharma since October 2022, with a focus on oncology, immuno-oncology, and CAR-T therapies. Prior to this role, Joseph held positions at Alexion Pharmaceuticals, Inc. as a Clinical Project Lead focusing on Rare Disease Hematology, and at AMAG Pharmaceuticals as Director of Clinical Operations specializing in Women's Health and Hematology. Joseph has extensive experience at Shire and Janssen, contributing to clinical programs in rare diseases and cardiovascular/metabolics, particularly Alzheimer’s disease. Early career experience includes a role as Senior Staff Scientist at Forest Laboratories, where Joseph was involved in regulatory document review and toxicology analysis. Joseph holds a Bachelor's degree in Biotechnology from Delaware Valley University, earned in 2002.